H. Zeidler and B. Amor, The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress, Annals of the Rheumatic Diseases, vol.70, issue.1, p.21163805, 2011.
DOI : 10.1136/ard.2010.135889

T. Alonso and J. , Utilidad y aplicaci??n en la pr??ctica cl??nica de los criterios CASPAR, Reumatolog??a Cl??nica, vol.6, pp.18-21, 2010.
DOI : 10.1016/j.reuma.2009.12.002

W. Tillett, L. Costa, D. Jadon, D. Wallis, C. Cavill et al., The ClASsification for Psoriatic ARthritis (CASPAR) Criteria - A Retrospective Feasibility, Sensitivity, and Specificity Study, The Journal of Rheumatology, vol.39, issue.1, pp.154-156, 2012.
DOI : 10.3899/jrheum.110845

V. Chandran, Spondyloarthritis: CASPAR criteria in early psoriatic arthritis, Nature Reviews Rheumatology, vol.39, issue.9, pp.503-504, 2012.
DOI : 10.1038/nrrheum.2012.121

L. Bogliolo, C. Alpini, R. Caporali, C. Scirè, R. Moratti et al., Antibodies to cyclic citrullinated peptides in psoriatic arthritis, J Rheumatol, vol.32, pp.511-515, 2005.

B. Vander-cruyssen, I. Hoffman, H. Zmierczak, M. Van-den-berghe, E. Kruithof et al., Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1145-1149, 2005.
DOI : 10.1136/ard.2004.032177

A. Marchesoni, A. Lurati, F. Desiati, V. Rossi, and N. Battafarano, Antibodies to cyclic citrullinated peptides in psoriatic arthritis: do classification criteria affect study results?, J Rheumatol, vol.33, pp.435-436, 2006.

D. Caspi, M. Anouk, I. Golan, D. Paran, I. Kaufman et al., Synovial fluid levels of anti???cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis, Arthritis & Rheumatism, vol.28, issue.1, pp.53-56, 2006.
DOI : 10.1002/art.21691

L. Candia, J. Marquez, C. Gonzalez, A. Santos, J. Londoño et al., Low Frequency of Anticyclic Citrullinated Peptide Antibodies in Psoriatic Arthritis But Not in Cutaneous Psoriasis, JCR: Journal of Clinical Rheumatology, vol.12, issue.5, pp.226-229, 2006.
DOI : 10.1097/rhu.0000242779.73390.51

N. Inanc, E. Dalkilic, S. Kamali, E. Kasapoglu-günal, Y. Elbir et al., Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis, Clinical Rheumatology, vol.42, issue.5, pp.17-23, 2007.
DOI : 10.1007/s10067-006-0214-5

S. Shibata, Y. Tada, M. Komine, N. Hattori, S. Osame et al., Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis, Journal of Dermatological Science, vol.53, issue.1, pp.34-39, 2009.
DOI : 10.1016/j.jdermsci.2008.06.008

H. Maejima, R. Aki, A. Watarai, K. Shirai, Y. Hamada et al., Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients, The Journal of Dermatology, vol.31, issue.4, pp.339-345, 2010.
DOI : 10.1111/j.1346-8138.2010.00814.x

S. Dalmády, M. Kiss, L. Képíró, L. Kovács, G. Sonkodi et al., Higher Levels of Autoantibodies Targeting Mutated Citrullinated Vimentin in Patients with Psoriatic Arthritis Than in Patients with Psoriasis Vulgaris, Clinical and Developmental Immunology, vol.10, issue.6, pp.474028-474038, 2013.
DOI : 10.1016/j.jbspin.2011.02.009

M. Feletar, J. Brockbank, C. Schentag, V. Lapp, and D. Gladman, Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients, Annals of the Rheumatic Diseases, vol.63, issue.2, pp.156-161, 2004.
DOI : 10.1136/ard.2003.006775

J. Sellam, Y. Allanore, F. Batteux, C. Deslandre, B. Weill et al., Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate, Joint Bone Spine, vol.72, issue.1, pp.48-52, 2005.
DOI : 10.1016/j.jbspin.2004.03.003

N. Poulalhon, E. Begon, C. Lebbé, F. Lioté, M. Lahfa et al., A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity, British Journal of Dermatology, vol.3, issue.2, pp.329-336, 2007.
DOI : 10.1111/j.1365-2133.2004.05960.x

H. Bacquet-deschryver, F. Jouen, M. Quillard, J. Ménard, V. Goëb et al., Impact of Three Anti-TNF?? Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients, Journal of Clinical Immunology, vol.18, issue.Suppl 2, pp.445-455, 2008.
DOI : 10.1007/s10875-008-9214-3

V. Viana, J. De-carvalho, J. De-moraes, C. Saad, R. Ac-de et al., Pesquisa de autoanticorpos em pacientes com artrite psori??sica sob terapia anti-TNF??, Revista Brasileira de Reumatologia, vol.50, issue.3, pp.225-234, 2010.
DOI : 10.1590/S0482-50042010000300003
URL : http://doi.org/10.1590/s0482-50042010000300003

J. Hoffmann, M. Hartmann, A. Enk, and E. Hadaschik, Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction, British Journal of Dermatology, vol.187, issue.6, pp.1355-1358, 2011.
DOI : 10.1111/j.1365-2133.2011.10555.x

R. Saraceno, F. Specchio, T. Torres, S. Nisticò, S. Rizza et al., The role of antinuclear autoantibodies in patients with psoriasis treated with anti???tumor necrosis factor-alpha agents: A retrospective long-term study, Journal of the American Academy of Dermatology, vol.66, issue.5, pp.180-182, 2012.
DOI : 10.1016/j.jaad.2011.06.008

V. Lora, C. Bonaguri, P. Gisondi, F. Sandei, L. Battistelli et al., Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab, Immunologic Research, vol.6, issue.2-3, pp.382-389, 2013.
DOI : 10.1007/s12026-013-8410-2

R. Saraceno, M. Chimenti, and S. Chimenti, The significance of the development of antinuclear antibodies during infliximab treatment, Journal of the American Academy of Dermatology, vol.69, issue.2, 2013.
DOI : 10.1016/j.jaad.2013.03.020

M. Chimenti, F. Spinelli, A. Giunta, F. Martinelli, R. Saraceno et al., Emergence of Antinuclear Antibodies in Psoriatic Patients Treated with Infliximab: Personal Experience and Literature Review, Drug Development Research, vol.66, issue.Suppl. 1, pp.61-63, 2014.
DOI : 10.1002/ddr.21198

P. Meroni and P. Schur, ANA screening: an old test with new recommendations, Annals of the Rheumatic Diseases, vol.69, issue.8, pp.1420-1422, 2010.
DOI : 10.1136/ard.2009.127100

F. Brito, A. Santos, S. Ferreira, G. Pedrosa, W. Gradisse et al., Detec????o de anticorpos antinucleares por imunofluoresc??ncia indireta em c??lulas HEp-2: definindo a dilui????o de triagem adequada para o diagn??stico das doen??as reum??ticas autoimunes, Revista Brasileira de Reumatologia, vol.54, issue.1, pp.13-20, 2014.
DOI : 10.1016/j.rbr.2014.01.002

N. Sönnichsen, G. Apostoloff, E. Apostoloff, and L. Krell, Immunologic and clinical studies on psoriasis], Dtsch Gesundheitswesen, vol.21, pp.973-978, 1966.

S. Johnson, C. Schentag, and D. Gladman, Autoantibodies in biological agent naive patients with psoriatic arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.770-772, 2005.
DOI : 10.1136/ard.2004.031286

Q. Li, D. Karp, J. Quan, V. Branch, J. Zhou et al., Risk factors for ANA positivity in healthy persons, Arthritis Research & Therapy, vol.13, issue.2, pp.10-1186, 2011.
DOI : 10.1007/s10067-007-0601-6